| Acromegaly improved with sandostatin LAR treatment |
|
Young Ju Lee, Hyun Chul Jo, Seung Hyung Ha, Ji Wong Jang, Jong Hwa Kim, Heung Kon Hwang |
|
Cardiology Division, Department of Internal Medicine, Yeungnam University Hospital1 |
| 증례 : 말단비대증 환자에서 임상 호전을 보인 1예 |
|
이영주&#;조현철&#;하승형&#;장지원&#;김종화&#;황흥곤, Hyun Chul Jo, Seung Hyung Ha, Ji Wong Jang, Jong Hwa Kim, Heung Kon Hwang |
|
|
|
|
|
|
| Abstract |
|
Cardiovascular disease is the most frequent cause of death in patients with acromegaly. Recently, long-term treatment with a somatostatin analogue (Sandostatin LAR) has been shown to be effective in controlling growth hormone (GH) and insulin like growth factor-1 (IGF-1) hypersecretion in most patients with acromegaly. Along with the effectiveness in the hormone profile, Sandostatin LAR has been reported to be effective for tumor mass shrinkage and clinical symptom improvement. We have encountered a female acromeglic patient with severe dilated cardiomyopathy and the patient was treated with Sandostatin LAR After treatment for 12 months, as seen by follow up echocardiography, the overall cardiac function was significantly improved. We report the case with a review of the literature. (Korean J Med 73:643-646, 2007) |
| Key Words:
Acromegaly, Dilated cardiomyopathy |
|
PDF Links
Full text via DOI
Download Citation
